All Phenotypes Tg(Kap-icre)29066/2Sig MGI Mouse

renal/urinary system

• hypercitraturia in tamoxifen treated mice

• however, microlithiasis is not seen and no changes in urine excretion, urea level, ketone bodies level, or creatinuria are seen

increased urine magnesium level ( J:238264 )

• in tamoxifen treated mice

decreased urine pH ( J:238264 )

• urinary pH is more acidic in tamoxifen treated mice than in controls

increased urine phosphate level ( J:238264 )

• in tamoxifen treated mice

increased urine microalbumin level ( J:238264 )

• microalbuminuria in tamoxifen treated mice

increased urine uric acid level ( J:238264 )

• uric acid levels are increased 3-fold in the urine of tamoxifen treated mice

abnormal kidney morphology ( J:238264 )

• marker analysis indicates that kidneys from tamoxifen treated mice show epithelial-mesenchymal transition-like changes, with loss of epithelial markers and overexpression of fibronectin

• lipid deposits in the internal part of the renal cortex of tamoxifen treated mice

• however, glomerulosclerosis is not seen

enlarged kidney ( J:238264 )

• enlarged kidneys in tamoxifen treated mice

increased kidney weight ( J:238264 )

increased kidney glycogen level ( J:238264 )

• glycogen accumulation in the tubules in the external part of the kidney cortex of tamoxifen treated mice

abnormal kidney cortex morphology ( J:238264 )

• alterations of the kidney cortex with a clarification and enlargement of tubular epithelial cells in tamoxifen treated mice

• lipid deposits in the internal part of the renal cortex of tamoxifen treated mice

abnormal podocyte morphology ( J:238264 )

• marker analysis indicates podocyte damage in tamoxifen treated mice

abnormal renal tubule morphology ( J:238264 )

• tubule dilation due to massive accumulation of glycogen

homeostasis/metabolism

increased blood uric acid level ( J:238264 )

• plasma uric acid concentrations are slightly higher in mice treated with tamoxifen at 6-8 weeks of age compared with controls

• however, plasma cholesterol, triglycerides, lactate, and blood urea nitrogen levels are normal in tamoxifen treated mice

increased kidney glycogen level ( J:238264 )

• glycogen accumulation in the tubules in the external part of the kidney cortex of tamoxifen treated mice

abnormal urine homeostasis ( J:238264 )

• hypercitraturia in tamoxifen treated mice

• however, microlithiasis is not seen and no changes in urine excretion, urea level, ketone bodies level, or creatinuria are seen

increased urine magnesium level ( J:238264 )

• in tamoxifen treated mice

decreased urine pH ( J:238264 )

• urinary pH is more acidic in tamoxifen treated mice than in controls

increased urine phosphate level ( J:238264 )

• in tamoxifen treated mice

increased urine microalbumin level ( J:238264 )

• microalbuminuria in tamoxifen treated mice

increased urine uric acid level ( J:238264 )

• uric acid levels are increased 3-fold in the urine of tamoxifen treated mice

growth/size/body

enlarged kidney ( J:238264 )

• enlarged kidneys in tamoxifen treated mice

increased kidney weight ( J:238264 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
glycogen storage disease Ia		DOID:2749	OMIM:232200	J:238264

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/16/2024 MGI 6.23